ClinicalTrials.gov record
Completed Phase 2 Interventional

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

ClinicalTrials.gov ID: NCT05907291

Public ClinicalTrials.gov record NCT05907291. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

Study identification

NCT ID
NCT05907291
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Enrollment
38 participants

Conditions and interventions

Interventions

  • atumelnant (CRN04894) Drug

Drug

Eligibility (public fields only)

Age range
16 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 2, 2023
Primary completion
Aug 21, 2025
Completion
Aug 21, 2025
Last update posted
Sep 22, 2025

2023 – 2025

United States locations

U.S. sites
8
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
Crinetics Study Site Pasadena California 91105
Crinetics Study Site Ann Arbor Michigan 48109
Crinetics Study Site Minneapolis Minnesota 55454
Crinetics Study Site St Louis Missouri 63110
Crinetics Study Site Morehead City North Carolina 28557
Crinetics Study Site Cleveland Ohio 44195
Crinetics Study Site Philadelphia Pennsylvania 19104
Crinetics Study Site East Providence Rhode Island 02915

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05907291, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 22, 2025 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05907291 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →